S2N.Bio Starts Alzheimer’s Cell Therapy Transfer to Melbourne Facility
S2N.Bio has initiated the transfer of its Alzheimer's cell therapy technology to Cell Therapies’ GMP-certified facility in Melbourne. This move aims to advance the development and manufacturing of cell therapies targeting Alzheimer's disease, leveraging the Melbourne facility's capabilities to support clinical and commercial production.
BioSpectrum Asia··Melbourne




